Wordt geladen...
The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidenc...
Bewaard in:
| Gepubliceerd in: | Cells |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7824419/ https://ncbi.nlm.nih.gov/pubmed/33375410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10010030 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|